- Investor's Business Daily•2 days ago
Gilead's NASH drug is "clearly active and promising," but Intercept Pharmaceuticals remains one to two years ahead, RBC says.
- Barrons.com•2 days ago
Despite yesterday's news about its NASH treatment, Gabelli's Jing He argues that Gilead Sciences' (GILD) still needs an acquisition. She explains why: On October 21, 2016, Gilead announced PhII results ...
- Business Insider•2 days ago
Close to 8% of the Georgian population is living with hepatitis C, an infection that can...
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.52|
|Avg Vol (3m)||10,641,496|
|Dividend & Yield||1.88 (2.53%)|